Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 11/20 | 0.46 |
| ▸ | SLC16A1 | P53985 | 11/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.42 |
| ▸ | MCTS1 | Q9ULC4 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608923 | 0.91 | PDE4B (0.46) | SLC16A3SLC16A1PDE4BMCTS1PDE4D | |
| SCHEMBL3606692 | 0.90 | PDE4B (0.45) | SLC16A3SLC16A1PDE4BMCTS1PDE4D | |
| SCHEMBL3603031 | 0.83 | PDE4B (0.45) | SLC16A3SLC16A1PDE4BMCTS1PDE4D | |
| SCHEMBL3606095 | 0.81 | PDE4B (0.44) | SLC16A3SLC16A1PDE4BPDE4D | |
| SCHEMBL4188742 | 0.81 | PDE4B (0.46) | SLC16A3SLC16A1PDE4BMCTS1PDE4D | |
| SCHEMBL3607474 | 0.80 | PDE4B (0.42) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3604755 | 0.80 | PDE4B (0.46) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3615330 | 0.80 | PDE4B (0.49) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3611624 | 0.78 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4194985 | 0.78 | PDE4B (0.42) | PDE4BPDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495017-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-24 | — | — | US | claimed |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | HOPPER ALLEN | 2007-08-30 | — | — | US | claimed |
| EP-1631568-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2006-03-08 | — | — | EP | claimed |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-11-18 | — | — | US | claimed |
| WO-2004094411-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | claimed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-09-03 | — | — | US | disclosed |
| US-7495017-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | HOPPER ALLEN | 2007-08-30 | — | — | US | disclosed |
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| US-7226930-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICAL CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | disclosed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1631568-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-11-18 | — | — | US | disclosed |
| WO-2004094411-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | SLC16A3 1854/4885SLC16A1 3731/4885PDE4B 2/4885 |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | SLC16A3 1854/4885SLC16A1 3731/4885PDE4B 2/4885 |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | SLC16A3 1854/4885SLC16A1 3731/4885PDE4B 2/4885 |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | SLC16A3 1854/4885SLC16A1 3731/4885PDE4B 2/4885 |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | SLC16A3 1854/4885SLC16A1 3731/4885PDE4B 2/4885 |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | SLC16A3 1854/4885SLC16A1 3731/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.